admin A vaccine being developed by the American company Novavax in collaboration with the Serum Institute of India will begin its trials and would be launched in the month of September for use.
This announcement was made by the CEO of the Serum Institute of India. Novavax is working with SII because the trials in India can take place at a faster pace and with less resources.
In the initial testing done on the vaccine, it was found that it is 89% effective and works well with the variants being discovered may it be the African one or the UK.
Adar made this announcement via a tweet and was happy to announce another partnership. Prior to this, Adar had also talked about wanting to launch the vaccine in the month of June, but clarified with his tweet that now it will be in the month of September.
The drug controller of India DCGI has cleared the vaccine for trials and once the trials are done and the vaccine can be proved effective with the support of data, the DCGI will only approve it for use.
In the United States, three vaccines have already been developed, Pfizer with an efficacy of 95%, Moderna with an efficacy of 94% and Johnson and Johnson vaccine which is a single-dose vaccine. Both these vaccines have been approved in the United States and the vaccination program is going on in full swing.
SII has the biggest vaccine making capacity in the world and can manufacture thousands of doses in the minutes. The trials will be taking place from this week onwards and the trials will take place at varied locations throughout India to make sure that the vaccine is effective.
The number of participants in this study are 1,140 chosen from all across the country to ensure that a balance is created in the testing process. More people will also be enrolled for the trails. The trials taking place will be bridging both the phase 1 and phase 2 of the trails so that a quick rollout of the vaccine can take place.
Magazine 
